Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.

Inclusion Criteria:

• undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair)
• English as first language

Exclusion Criteria:

• patients undergoing concomitant posterior repair, vaginal vault suspension, or any other intra-peritoneal surgeries including hysterectomy
• NSAID use within 7 days of surgery
• steroid use within 10 days
• daily opioid use in the last 3 months
• long acting opioids within 3 days
• any opioids within 24h
• patients unable to consent for themselves
• patients allergic to meloxicam or bupivacaine
• pregnant or lactating patients